Printer Friendly

BACCHUS VASCULAR GETS IDE FOR DEEP VEIN THROMBOSIS SYSTEM.

Bacchus Vascular, Santa Clara, Calif., has received FDA approval of an Investigational Device Exemption (IDE) for the treatment of Deep Vein Thrombosis (DVT). Deep vein thrombosis occurs when blood clots form in the deep blood vessels of the legs. These blood clots can block flow from the legs back to the heart and lungs. In some cases clot pieces may travel to the lungs, which can be fatal. Approximately 400,000 Americans are affected by DVT annually.

The Bacchus Fino(TM) System is a proprietary minimally invasive device designed to remove blood clots from peripheral veins. The Fino enables rapid disruption and removal of deep vein thrombus. Physicians have already used the Fino System to successfully treat patients in Europe, Australia and Argentina.

"The Fino system represents the advances and innovations that Bacchus Vascular has made in thrombus removal. We are very pleased that the Fino System has already received its IDE approval," said Mel Schatz, CEO and president of Bacchus Vascular. "We are confident that physicians will use these tools to successfully treat patients with deep vein thrombosis."

About Bacchus Vascular

Bacchus Vascular, Inc. is a rapidly emerging company focused on the discovery and development of innovative treatments for cardiovascular and peripheral vascular occlusive disease. Bacchus Vascular was founded in 1999 by Thomas J. Fogarty, M.D. Dr. Fogarty has over forty years of experience in the development of embolectomy and thrombectomy products. Dr. Fogarty has pioneered the field of minimally invasive surgery through his inventions and in the process redefined how cardiovascular, vascular, and general surgeries are performed today.

Since its inception, Bacchus Vascular has developed different and innovative lines of patented percutaneous products, including the Trellis and Solera systems. Both have recently received 510(k) clearance and are CE-Marked. The company believes that it is strategically well positioned for leveraging its unique technologies into becoming the leader in Thrombus Management. "Bacchus Vascular continues to build on its strong medical technology and add to its well regarded product family. We are extremely proud of this new Fino platform, and believe that it represents the most advanced generations of thrombectomy catheters," noted Dr. Fogarty.

For more information, call 408/980-8300 ext. 242 or visit http://www.bacchus-vascular.com.
COPYRIGHT 2002 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Comment:BACCHUS VASCULAR GETS IDE FOR DEEP VEIN THROMBOSIS SYSTEM.
Publication:Biotech Equipment Update
Article Type:Brief Article
Geographic Code:1USA
Date:May 1, 2002
Words:369
Previous Article:NELLCOR DEBUTS OXIMAX PULSE OXIMETRY SYSTEM.
Next Article:BSC GETS IDE APPROVAL TO BEGIN TAXUS IV CLINICAL TRIAL.
Topics:


Related Articles
BSC GETS IDE APPROVAL TO BEGIN TAXUS IV CLINICAL TRIAL.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |